Biosimilar etanercept: Extension study data

Data from 232 evaluable patients in the open-label extension of a double-blind, European Phase III trial in 596 patients with moderate to severe RA despite methotrexate therapy showed that once-weekly 50 mg subcutaneous

Read the full 334 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE